Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 1:38 AM
Ignite Modification Date:
2025-12-25 @ 1:38 AM
NCT ID:
NCT02577094
Brief Summary:
Determination of the maximum tolerated dose (MTD) of fractionated RIT with epratuzumab radiolabeled with yttrium-90 (90Y-epratuzumab) preceding a reduced conditioning regimen FB2A2 before allogeneic stem cell transplantation.
Detailed Description:
* Physical examination (screening and follow-up)
* Complete blood counts (screening and follow-up)
* Dosage of FLT3-ligand in plasma (screening and follow-up)
* Blood ionogramme, creatinine hepatic work-up (screening and follow-up)
* Left ventricular ejection fraction at pre-implant assessment
* Immunization test (screening and follow-up)
* Bone marrow aspiration or/and blood CD 22 immunophenotype for minimal residual disease evaluation (screening and follow-up)
* All exams which were initially abnormal and which are necessary for response evaluation and All exams which are needed in case of relapse suspicion.
* Pharmacokinetic of 90Y-hLL2
Study:
NCT02577094
Study Brief:
Protocol Section:
NCT02577094